Three-dimensional pharmacology, a subject ranging from ignorance to overstatements.
(2003) In Pharmacology and Toxicology 93(5). p.203-210- Abstract
- Stereoselectivity has been known to play a role in drug action for 100 years or more. Nevertheless, chiral drugs have been developed and used as racemates, neglecting the fact that they comprise mixtures of two or more compounds which may have quite different pharmacological properties. A very limited access to pure enantiomers in the past has been responsible for this unsatisfactory state of affairs. During the last 20 years, significant achievements have made it possible to perform stereoselective synthesis and analysis. Today, novel chiral drugs are as a rule developed as single enantiomers. Yet, studies of old racaemic drugs are still designed, performed and published without mention of the fact that two or more compounds are involved.... (More)
- Stereoselectivity has been known to play a role in drug action for 100 years or more. Nevertheless, chiral drugs have been developed and used as racemates, neglecting the fact that they comprise mixtures of two or more compounds which may have quite different pharmacological properties. A very limited access to pure enantiomers in the past has been responsible for this unsatisfactory state of affairs. During the last 20 years, significant achievements have made it possible to perform stereoselective synthesis and analysis. Today, novel chiral drugs are as a rule developed as single enantiomers. Yet, studies of old racaemic drugs are still designed, performed and published without mention of the fact that two or more compounds are involved. In recent years, a number of old racaemic drugs have been re-evaluated and re-introduced into the clinical area as the pure, active enantiomer (the eutomer). While in principle correct, the clinical benefit of this shift from a well established racaemate to a pure enantiomer often seems to be limited and sometimes exaggerated. Racaemic drugs with a deleterious enantiomer that does not contribute to the therapeutic effect (the distomer), may have been sorted out in the safety evaluation process. However, in the future any pharmacological study of racaemic drugs must include the pure enantiomers. This will generate new, valuable information on stereoselectivity in drug action and interaction (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/118746
- author
- Waldeck, Bertil LU
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pharmacology and Toxicology
- volume
- 93
- issue
- 5
- pages
- 203 - 210
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:14629731
- wos:000187107300001
- scopus:0346874450
- ISSN
- 1600-0773
- DOI
- 10.1046/j.1600-0773.2003.pto930502.x
- language
- English
- LU publication?
- yes
- id
- 49b9981d-e344-4e54-ba7c-795deb40ac4e (old id 118746)
- date added to LUP
- 2016-04-01 12:06:49
- date last changed
- 2022-02-18 18:06:12
@article{49b9981d-e344-4e54-ba7c-795deb40ac4e,
abstract = {{Stereoselectivity has been known to play a role in drug action for 100 years or more. Nevertheless, chiral drugs have been developed and used as racemates, neglecting the fact that they comprise mixtures of two or more compounds which may have quite different pharmacological properties. A very limited access to pure enantiomers in the past has been responsible for this unsatisfactory state of affairs. During the last 20 years, significant achievements have made it possible to perform stereoselective synthesis and analysis. Today, novel chiral drugs are as a rule developed as single enantiomers. Yet, studies of old racaemic drugs are still designed, performed and published without mention of the fact that two or more compounds are involved. In recent years, a number of old racaemic drugs have been re-evaluated and re-introduced into the clinical area as the pure, active enantiomer (the eutomer). While in principle correct, the clinical benefit of this shift from a well established racaemate to a pure enantiomer often seems to be limited and sometimes exaggerated. Racaemic drugs with a deleterious enantiomer that does not contribute to the therapeutic effect (the distomer), may have been sorted out in the safety evaluation process. However, in the future any pharmacological study of racaemic drugs must include the pure enantiomers. This will generate new, valuable information on stereoselectivity in drug action and interaction}},
author = {{Waldeck, Bertil}},
issn = {{1600-0773}},
language = {{eng}},
number = {{5}},
pages = {{203--210}},
publisher = {{Wiley-Blackwell}},
series = {{Pharmacology and Toxicology}},
title = {{Three-dimensional pharmacology, a subject ranging from ignorance to overstatements.}},
url = {{https://lup.lub.lu.se/search/files/2787090/623898.pdf}},
doi = {{10.1046/j.1600-0773.2003.pto930502.x}},
volume = {{93}},
year = {{2003}},
}